相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
Tetsuya Kouno et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis
Andreas E. Kremer et al.
LIVER INTERNATIONAL (2022)
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Christopher L. Bowlus et al.
JOURNAL OF HEPATOLOGY (2022)
Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis
Atsushi Tanaka et al.
JOURNAL OF HEPATOLOGY (2021)
Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid
John E. Eaton et al.
HEPATOLOGY (2020)
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study
Cynthia Levy et al.
JOURNAL OF HEPATOLOGY (2020)
Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial
Amardeep Khanna et al.
HEPATOLOGY (2019)
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Michael Trauner et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Gideon M. Hirschfield et al.
GUT (2018)
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C. Corpechot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response
Anna Reig et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Vanessa Dubois et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system
A. Dash et al.
TOXICOLOGY IN VITRO (2017)
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia
Kenichi Hosonuma et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
A COMPARATIVE STUDY OF PRURITUS IN PBC COHORTS FROM UK, USA AND ITALY
V. S. Hegade et al.
JOURNAL OF HEPATOLOGY (2015)
Unmet clinical need in autoimmune liver diseases
Jessica K. Dyson et al.
JOURNAL OF HEPATOLOGY (2015)
Primary biliary cirrhosis
Elizabeth J. Carey et al.
LANCET (2015)
The New Epidemiology of Primary Biliary Cirrhosis
Laura Griffiths et al.
SEMINARS IN LIVER DISEASE (2014)
Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid
Marco Carbone et al.
GASTROENTEROLOGY (2013)
Impact of Primary Biliary Cirrhosis on Perceived Quality of Life: The UK-PBC National Study
George F. Mells et al.
HEPATOLOGY (2013)
Sleep-Wake profiles in patients with primary biliary cirrhosis
Sara Montagnese et al.
LIVER INTERNATIONAL (2013)
Liver X Receptor β and Peroxisome Proliferator-Activated Receptor δ Regulate Cholesterol Transport in Murine Cholangiocytes
Xuefeng Xia et al.
HEPATOLOGY (2012)
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Njideka Momah et al.
LIVER INTERNATIONAL (2012)
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Keiko Iwaisako et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
Harold E. Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome
Christophe Corpechot et al.
JOURNAL OF HEPATOLOGY (2011)
American Association for the Study of Liver Diseases Endpoints Conference: Design and Endpoints for Clinical Trials in Primary Biliary Cirrhosis
Marina G. Silveira et al.
HEPATOLOGY (2010)
Fibrate therapy and renal function
Domenic A. Sica
CURRENT ATHEROSCLEROSIS REPORTS (2009)
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
Edith M. M. Kuiper et al.
GASTROENTEROLOGY (2009)
Regulation of Bile Acid and Cholesterol Metabolism by PPARs
Tiangang Li et al.
PPAR RESEARCH (2009)
Effect of fenofibrate on kidney function:: A 6-week randomized crossover trial in healthy people
Jean-Claude Ansquer et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Christophe Corpechot et al.
HEPATOLOGY (2008)
Modulation of PPAR activity via phosphorylation
Katherine A. Burns et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
Safety considerations with fibrate therapy
Michael H. Davidson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence
Julia L. Newton et al.
HEPATOLOGY (2006)
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid
A Parés et al.
GASTROENTEROLOGY (2006)
Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis
A Jacoby et al.
GUT (2005)
When Is Liver Biopsy Needed in the Diagnosis of Primary Biliary Cirrhosis?
Claudia O. Zein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2003)
Fenofibrate increases creatininemia by increasing metabolic production of creatinine
C Hottelart et al.
NEPHRON (2002)
Peroxisome proliferator-activated receptor α is restricted to hepatic parenchymal cells, not Kupffer cells:: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis
JM Peters et al.
CARCINOGENESIS (2000)
分享论文
